Products
Comprehensive catalog of pharmaceutical solutions. Browse categories and send inquiries directly.
All Products (882)
| Molecule | Drug Class / Mechanism | Oncology Type | Inquiry | |
|---|---|---|---|---|
Elotuzumab |
Anti-CD38 / SLAMF7 mAb | Hematologic (Multiple Myeloma) | ||
|
Molecule
Elotuzumab
Therapeutic Category
Immunotherapy (Monoclonal Antibody)
Oncology Type
Hematologic (Multiple Myeloma)
Drug Class / Mechanism
Anti-CD38 / SLAMF7 mAb |
||||
Elsubrutinib |
BTK Inhibitor | Hematologic (Lymphoma/CLL) | ||
|
Molecule
Elsubrutinib
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Lymphoma/CLL)
Drug Class / Mechanism
BTK Inhibitor |
||||
Eltanexor |
XPO1 (Exportin-1) Inhibitor | Hematologic (Multiple Myeloma/DLBCL) | ||
|
Molecule
Eltanexor
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Multiple Myeloma/DLBCL)
Drug Class / Mechanism
XPO1 (Exportin-1) Inhibitor |
||||
Elzovantinib |
MET Inhibitor | Solid Tumour | ||
|
Molecule
Elzovantinib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
MET Inhibitor |
||||
Enasidenib |
RET / MET / KRAS / IDH Inhibitor | Solid Tumour | ||
|
Molecule
Enasidenib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
RET / MET / KRAS / IDH Inhibitor |
||||
Ensartinib |
ALK / ROS1 / NTRK Inhibitor | Solid Tumour | ||
|
Molecule
Ensartinib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
ALK / ROS1 / NTRK Inhibitor |
||||
Entinostat |
HDAC Inhibitor | Hematologic (Lymphoma) | ||
|
Molecule
Entinostat
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Lymphoma)
Drug Class / Mechanism
HDAC Inhibitor |
||||
Entospletinib |
SYK / Multi-Kinase Inhibitor | Hematologic | ||
|
Molecule
Entospletinib
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic
Drug Class / Mechanism
SYK / Multi-Kinase Inhibitor |
||||
Entrectinib |
ALK / ROS1 / NTRK Inhibitor | Solid Tumour | ||
|
Molecule
Entrectinib
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
ALK / ROS1 / NTRK Inhibitor |
||||
Envafolimab |
Anti-PD-1 mAb | Both (Solid & Hematologic) | ||
|
Molecule
Envafolimab
Therapeutic Category
Immunotherapy (Checkpoint Inhibitor)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Anti-PD-1 mAb |
||||
Enzomenib |
EZH2 / Menin Inhibitor | Hematologic | ||
|
Molecule
Enzomenib
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic
Drug Class / Mechanism
EZH2 / Menin Inhibitor |
||||
Epcoritamab |
Bispecific T-Cell Engager | Both (Solid & Hematologic) | ||
|
Molecule
Epcoritamab
Therapeutic Category
Immunotherapy (Bispecific Antibody)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Bispecific T-Cell Engager |
||||
ElotuzumabImmunotherapy (Monoclonal Antibody) |
|
|
Therapeutic Category
Immunotherapy (Monoclonal Antibody)
Oncology Type
Hematologic (Multiple Myeloma)
Drug Class / Mechanism
Anti-CD38 / SLAMF7 mAb |
|
ElsubrutinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Lymphoma/CLL)
Drug Class / Mechanism
BTK Inhibitor |
|
EltanexorTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Multiple Myeloma/DLBCL)
Drug Class / Mechanism
XPO1 (Exportin-1) Inhibitor |
|
ElzovantinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
MET Inhibitor |
|
EnasidenibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
RET / MET / KRAS / IDH Inhibitor |
|
EnsartinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
ALK / ROS1 / NTRK Inhibitor |
|
EntinostatTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic (Lymphoma)
Drug Class / Mechanism
HDAC Inhibitor |
|
EntospletinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic
Drug Class / Mechanism
SYK / Multi-Kinase Inhibitor |
|
EntrectinibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Solid Tumour
Drug Class / Mechanism
ALK / ROS1 / NTRK Inhibitor |
|
EnvafolimabImmunotherapy (Checkpoint Inhibitor) |
|
|
Therapeutic Category
Immunotherapy (Checkpoint Inhibitor)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Anti-PD-1 mAb |
|
EnzomenibTargeted Therapy |
|
|
Therapeutic Category
Targeted Therapy
Oncology Type
Hematologic
Drug Class / Mechanism
EZH2 / Menin Inhibitor |
|
EpcoritamabImmunotherapy (Bispecific Antibody) |
|
|
Therapeutic Category
Immunotherapy (Bispecific Antibody)
Oncology Type
Both (Solid & Hematologic)
Drug Class / Mechanism
Bispecific T-Cell Engager |
|